{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:57Z","timestamp":1776211257004,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009192","name":"Alberta Innovates","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009192","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Genomics"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.xgen.2026.101215","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:26:17Z","timestamp":1775665577000},"page":"101215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Revealing cancer glycome drivers using CRISPR activation screens"],"prefix":"10.1016","volume":"6","author":[{"given":"Mathieu","family":"Decloquement","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4579-1048","authenticated-orcid":false,"given":"Matthew S.","family":"Macauley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xgen.2026.101215_bib1","article-title":"CRISPR activation screens map the genomic landscape of cancer glycome remodeling","volume":"6","author":"Daly","year":"2026","journal-title":"Cell Genom."},{"key":"10.1016\/j.xgen.2026.101215_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2026.111249","article-title":"Writers and readers of sialylation in immunoregulation in cancer","volume":"302","author":"Decloquement","year":"2026","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xgen.2026.101215_bib3","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.molcel.2019.05.017","article-title":"An Atlas of Human Glycosylation Pathways Enables Display of the Human Glycome by Gene Engineered Cells","volume":"75","author":"Narimatsu","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.xgen.2026.101215_bib4","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2015024118","article-title":"Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7","volume":"118","author":"Wisnovsky","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xgen.2026.101215_bib5","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.cell.2014.09.029","article-title":"Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation","volume":"159","author":"Gilbert","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.xgen.2026.101215_bib6","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2026102118","article-title":"Probing the binding specificities of human Siglecs by cell-based glycan arrays","volume":"118","author":"B\u00fcll","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xgen.2026.101215_bib7","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41375-024-02454-w","article-title":"The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9","volume":"39","author":"Krishnamoorthy","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.xgen.2026.101215_bib8","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","article-title":"CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.xgen.2026.101215_bib9","article-title":"The unique molecular recognition features of Siglec-10: structural insights into sialoglycan and antibody interactions","author":"Sobczak","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.xgen.2026.101215_bib10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41573-020-00093-1","article-title":"The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans","volume":"20","author":"Smith","year":"2021","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Cell Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666979X26000777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666979X26000777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T23:12:03Z","timestamp":1776208323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666979X26000777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2666979X26000777"],"URL":"https:\/\/doi.org\/10.1016\/j.xgen.2026.101215","relation":{},"ISSN":["2666-979X"],"issn-type":[{"value":"2666-979X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revealing cancer glycome drivers using CRISPR activation screens","name":"articletitle","label":"Article Title"},{"value":"Cell Genomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xgen.2026.101215","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.xgen.2026.101139","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101215"}}